ReviewCancers2019
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review.Frontiers in medicine · 2022Pooled it
- Article
- Advancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer.Journal of Zhejiang University. Science. B · 2025Review
- Imaging at the nexus: how state of the art imaging techniques can enhance our understanding of cancer and fibrosis.Journal of translational medicine · 2024Review
- Impact of [Annals of nuclear medicine · 2024Article
- Diagnostic accuracy of anti-3-[European journal of nuclear medicine and molecular imaging · 2024Article
- Contribution of the L-Type Amino Acid Transporter Family in the Diagnosis and Treatment of Prostate Cancer.International journal of molecular sciences · 2023Review
- Targeted Molecular Imaging as a Biomarker in Urologic Oncology.The Urologic clinics of North America · 2023Review
- Clinical advancement of precision theranostics in prostate cancer.Frontiers in oncology · 2023Review
- Clinical practice in prostate PET imaging.Therapeutic advances in medical oncology · 2023Review
- Investigational PET tracers in neuro-oncology-What's on the horizon? A report of the PET/RANO group.Neuro-oncology · 2022Article
- Prostate Cancer Biochemical Recurrence Resulted Negative on [Tomography (Ann Arbor, Mich.) · 2022Article
- Article
- Beyond the Prognostic Value of 2-[Diagnostics (Basel, Switzerland) · 2022Review
- Detection Rate and Clinical Impact of PET/CT withBiomedicines · 2022Article
- Contribution of LAT1-4F2hc in Urological Cancers via Toll-like Receptor and Other Vital Pathways.Cancers · 2022Review
- Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends.Cancers · 2021Review
- [Positron emission tomography with computed tomography/magnetic resonance imaging for primary staging of prostate cancer].Der Radiologe · 2021Review
- Radiomics analysis of 18F-Choline PET/CT in the prediction of disease outcome in high-risk prostate cancer: an explorative study on machine learning feature classification in 94 patients.European radiology · 2021Article
- 18F-Fluciclovine Positron Emission Tomography in Prostate Cancer: A Systematic Review and Diagnostic Meta-Analysis.Diagnostics (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trans-1-amino-3-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.